ASH17
News/ News/ Oncology/ Top stories/ US
Roche/AbbVie combination could raise standards in CLL
Richard Staines
AbbVie, ASH17, blood cancer, chronic lymphocytic leukaemia, Roche
0 Comment
Gilead/ News/ News/ Oncology/ R&D
Gilead goes full throttle on CAR-Ts with $567m acquisition
Richard Staines
ASH17, cancer, CAR T, Gilead, Novartis
0 Comment
Gilead hopes CDL technology will create therapies targeting solid tumours
‘Cure for hemophilia within reach’ as BioMarin and Spark gene therapies shine
Andrew McConaghie
ASH17, BioMarin, haemophilia, haemophilia A, haemophilia B
0 Comment
Spark and Pfizer’s gene therapy wows in haemophilia B
Andrew McConaghie
ASH17, haemophilia, haemophilia B, Spark Therapeutics
0 Comment
Cancer/ Oncology/ Quintiles - Oncol articles/ Views & Analysis/ Views and analysis
ASH 2017: CAR-T therapy and beyond
Richard Staines
American Society of Hematology (ASH) Annual Meeting, ASH17, blood cancer, cancer, CAR T, immunooncology, IQVIA
0 Comment